Ipsen, a global biotechnology specialty care group and Menarini have launched Adenuric (febuxostat) in France where they will co-promote the drug.
Subscribe to our email newsletter
Menarini said that it is planning to launch other drugs shortly, notably in UK, Germany and Ireland.
Thierry Poiraud, general manager of Menarini in France, said: “We are proud to be the first country in Europe to launch this very promising drug with Ipsen. In collaboration with rheumatologists and general practitioners I hope we can significantly improve the chronic management of this painful and frequent disease,which may lead to serious complications with a major impact on quality of life. ”
Etienne de Blois, deputy general manager of France operations at Ipsen said: “The launch of Adenuric will provide patients and physicians with a new treatment alternative in a condition with high unmet medical needs. It also strengthens Ipsen’s primary care franchise in France, the first country to launch the drug in Europe. Ipsen is proud to work with Menarini to make that achievement possible.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.